The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, May 24, 2016 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting. The Committee will discuss the safety and efficacy of Novo Nordisk’s Xultophy (insulin degludec and liraglutide) for the proposed indication of adjunct to diet and exercise to improve glycemic control in the treatment of adults with type 2 diabetes mellitus.

See the SAC Tracker report